Clinical trials: Stage 2 Hypertension
Essential Hypertension, Primary Hypercholesterolemia
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1018 and Coadministration of BR1018A and BR1018B in Healthy Adult Volunteers
The purpose of this clinical study is to evaluate the pharmacokinetics and the safety after administration of BR1018 and coadministration of BR1018A and BR1018B in healthy volunteers
- Trial name
- NCT06889012
- Testing
- BR1018, BR1018A, BR1018B
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
High Blood Pressure
Microcirculation and Inflammatory Markers in Patients With Resistant, Stages 1/2 Hypertension and Normal Blood Pressure
Nailfold videocapillaroscopy (NVC), Venous occlusion Plethysmography (VOP) and inflammatory biomarkers have been used to study endothelial function in patients with resistant hypertension, stages 1 and 2 hypertension and…
- Trial name
- MICRORAH (NCT02759276)
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Daniel Alexandre Bottino
Diabetes Mellitus, Type 2
Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes
The purpose of this study is to determine the safety and tolerability of pioglitazone-azilsartan, once daily (QD), in patients with type 2 diabetes mellitus.
- Trial name
- NCT01124656
- Testing
- Pioglitazone-Azilsartan
- Volunteers
- 26 people
- Sponsor
- Takeda
Glaucoma
Interactive Study to Increase Glaucoma Adherence to Treatment
Study participants who receive the I-SIGHT intervention will have higher rates of glaucoma treatment compliance (e.g., medication-taking and refill compliance, return for clinical follow-up) and more positive eye health outcomes…
- Trial name
- I-SIGHT (NCT00794170)
- Testing
- Telephone and Print based intervention
- Where
- 2 sites in United States
- Volunteers
- 312 people, healthy volunteers welcome
- Sponsor
- Emory University
Diabete Type 2, Hypertension
A Study to Compare the Pharmacokinetics and Safety of the ATB-U101 and ATB-U1011+ATB-U1012 and ATB-1011+ATB-1012 in Healthy Caucasian Participants
The goal of this Phase 1 clinical trial is to compare the pharmacokinetics and safety of a fixed-dose combination tablet (ATB-U101) versus co-administration of its individual components in healthy Caucasian adult volunteers.
- Trial name
- NCT07590466
- Testing
- ATB-U101, ATB-1011, ATB-U1011
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Autotelicbio
Hypertension
Aliskiren Study of Safety and Efficacy in Senior Hypertensives
This study is designed to compare the blood pressure lowering efficacy of aliskiren, a combination of aliskiren plus amlodipine, and ramipril in elderly patients with mild to moderate hypertension.
- Trial name
- ASSESS (NCT01922141)
- Testing
- Aliskiren, Amlodipine, Ramipril
- Sponsor
- Novartis Pharmaceuticals
Hypertension
Blood Pressure Lowering Ability and Safety of an Olmesartan and Amlodipine Based Treatment Regimen in Patients With Stage I and Stage II Hypertension
This study will be conducted to assess the efficacy and safety of an amlodipine/olmesartan treatment regimen in stage 1 and stage 2 hypertensive subjects.
- Trial name
- NCT00527514
- Testing
- Amlodipine, Olmesartan medoxomil plus amlodipine
- Where
- 18 sites in United States
- Volunteers
- 185 people
- Sponsor
- Daiichi Sankyo
Hypertension
Assessment of the Effectiveness of OLMETEC® and OLMETEC PLUS® for Treatment of Hypertension in Stage I and II Patients (Study P05254)(COMPLETED)
The purpose of this study is to determine the efficiency of Olmesartan medoxomile (OLMETEC®) alone or in combination with hydrochlorothiazide (OLMETEC PLUS®) in the reduction of arterial blood pressure in patients with light to…
- Trial name
- NCT00811226
- Testing
- olmesartan medoxomile alone or combined with hydrochlorothiazide,
- Volunteers
- 450 people
- Sponsor
- Schering-Plough
End Stage Renal Disease, Hypertension
Electronic Decision Support for Deprescribing in Patients on Hemodialysis
Dialysis patients are prescribed an average of 10-12 medications per day, from up to 4-5 different clinicians and have the heaviest pill burden of all chronic conditions given their degree of comorbidity.
- Conditions
- End Stage Renal Disease, Hypertension, Diabete Type 2, Renal Failure Chronic
- Trial name
- MedSafer-HD (NCT05585268)
- Testing
- Medication reconciliation supplemented with MedSafer and deprescribing brochures
- Where
- Canada
- Volunteers
- 195 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Isolated Systolic Hypertension, Endothelial Dysfunction
Oral 6R-BH4 for the Treatment of Isolated Systolic Hypertension and Endothelial Dysfunction
This study is designed to assess the safety and efficacy of twice-daily oral dosing of 6R-BH4 to improve endothelial function, reduce systolic blood pressure and reduce arterial stiffness.
- Trial name
- NCT00802893
- Testing
- 6R-BH4
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Johns Hopkins University
Pulmonary Arterial Hypertension, Pulmonary Hypertension Due to Lung Diseases
A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD
This Phase 3, 2-part, open-label, multicenter study aims to demonstrate the safety and tolerability of L606 in patients with PAH or PH-ILD.
- Trial name
- NCT04691154
- Testing
- L606 inhalation suspension
- Where
- 8 sites in United States
- Volunteers
- 28 people
- Sponsor
- Liquidia Technologies, Inc.
Biliary Tract Cancers, Intrahepatic Cholangiocarcinoma (Icc)
Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer
The purpose of this study is to evaluate the anti-tumor efficacy of daraxonrasib monotherapy in patients with unresectable or advanced/metastatic, KRAS-mutant BTC who have progressed on or are intolerant of 1st line systemic…
- Conditions
- Biliary Tract Cancers, Intrahepatic Cholangiocarcinoma (Icc), Extrahepatic Cholangiocarcinoma, Gallbladder Carcinoma
- Trial name
- NCT07793253
- Testing
- Daraxonrasib
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Hypertension
Cut Your Pressure Too: The Altadena Barbershop Blood Pressure Study, Phase 2 (Intervention Pilot Study)
African American men have the highest risk of any group for early death \& disability from high blood pressure (BP). Clinical investigations in Dallas, TX demonstrated that African American men with high BP are able to improve…
- Trial name
- NCT02198144
- Testing
- barbershop-based BP measurement
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Cedars-Sinai Medical Center
Open-Angle Glaucoma, Ocular Hypertension
A Phase 2 Study of Punctal Placement of the Latanoprost Punctal Plug Delivery System (L-PPDS)
The study objective is to compare IOP and safety outcomes based on plug placement (upper or lower puncta).
- Trial name
- NCT00821002
- Testing
- Latanoprost
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Mati Therapeutics Inc.
Hypertension
A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx
This study evaluated the effect of ISIS 757456 (IONIS-AGT-LRx) on plasma angiotensinogen (AGT) and systolic blood pressure (SBP) in uncontrolled hypertensive participants who were on two to three antihypertensive medications.
- Trial name
- NCT04083222
- Testing
- ISIS 757456
- Where
- 9 sites in United States
- Volunteers
- 26 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Hypertension
A Phase 2 Study to Explore the Dose of HCP1803 in Patients With Essential Hypertension
A multicenter, randomized, double-blind, parallel, phase 2 study to explore the dose of HCP1803 in patients with essential hypertension
- Trial name
- HM_APOLLO (NCT04959305)
- Testing
- HCP1803-3, RLD2003, RLD2004
- Where
- South Korea
- Volunteers
- 245 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Elevated Intraocular Pressure
A Study of AR-12286 in Patient With Elevated Intraocular Pressure (IOP)
Double-masked, randomized, multi-center, placebo-controlled parallel-comparison of AR-12286.
- Trial name
- NCT00902200
- Testing
- AR-12286, AR-12286 vehicle
- Where
- 8 sites in United States
- Volunteers
- 89 people
- Sponsor
- Aerie Pharmaceuticals
HFrEF - Heart Failure With Reduced Ejection Fraction, HFpEF - Heart Failure With Preserved Ejection Fraction
Study of JK07 in Patients With Heart Failure and WHO Group 2 Combined Post- and Pre-Capillary Pulmonary Hypertension
This is a Phase 2a, open-label, multiple-dose study to assess the safety, tolerability, and efficacy of JK07 in participants 18 to 85 years of age with diagnosed HF and cpcPH.
- Conditions
- HFrEF - Heart Failure With Reduced Ejection Fraction, HFpEF - Heart Failure With Preserved Ejection Fraction, Group 2 Pulmonary Hypertension
- Trial name
- RENEU-PH (NCT07221513)
- Testing
- JK07
- Where
- United States
- Sponsor
- Salubris Biotherapeutics Inc
Glaucoma
Study to Evaluate Drug-drug Interaction, Safety and Tolerability in Case of the Co-administration of D565 and D930
This study is a randomized, open-label, 2-period, parallel group, multiple-dose phase 1 study to evaluate drug-drug Interaction, safety and tolerability in case of the co-administration of D565 and D930, in healthy male subjects
- Trial name
- NCT05207761
- Testing
- D565, D930
- Where
- South Korea
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Hypertension in Pregnancy
Chronic Hypertension and Pregnancy 2 (CHAP2) Pilot Project
The CHAP2 study is designed to provide preliminary data for a larger multicenter study to assess whether treatment of stage 1 hypertension (HTN) in pregnancy improves maternal and or neonatal outcomes.
- Trial name
- CHAP2 (NCT05989581)
- Testing
- Labetalol or Nifedipine
- Where
- United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham